Filing Details

Accession Number:
0001209191-21-052285
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-18 17:30:22
Reporting Period:
2021-08-16
Accepted Time:
2021-08-18 17:30:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1662774 Cortexyme Inc. CRTX Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1770823 Margaret Mcloughlin C/O Cortexyme, Inc.
269 East Grand Ave.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-16 6,000 $17.00 6,000 No 4 M Direct
Common Stock Disposition 2021-08-16 3,056 $94.55 2,944 No 4 S Direct
Common Stock Disposition 2021-08-16 1,044 $95.57 1,900 No 4 S Direct
Common Stock Disposition 2021-08-16 1,429 $96.51 471 No 4 S Direct
Common Stock Disposition 2021-08-16 423 $97.55 48 No 4 S Direct
Common Stock Disposition 2021-08-16 48 $98.90 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-08-16 6,000 $0.00 6,000 $17.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
85,911 2029-05-07 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.06 to $95.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.12 to $97.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.22 to $97.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022.